Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.

被引：0
|
作者：
Casinello, J
Dorta, J
Aguiar, J
Pérez-Carrión, J
Castellanos, J
Valladares, J
Sevilla, J
Belón, J
Fernández, J
Casal, J
机构：
[1] H Meixoeiro, Pontevedra, Spain
[2] H del Bierzo, Leon, Spain
[3] H Virgen de las Nieves, Granada, Spain
[4] H Virgen de la Victoria, Malaga, Spain
[5] H Juan Canalejo, La Coruna, Spain
[6] H Xeral Cies, Pontevedra, Spain
[7] H Princesa, Madrid, Spain
[8] H Gran Canarias, Madrid, Spain
[9] Na Sa Candelaria, Tenerife, Spain
[10] H Guadalajara, Tenerife, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198P
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [21] Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer.
    Vanhoefer, UJ
    Mayer, S
    Achterrath, W
    Hense, J
    Omidi, S
    Frings, S
    Harstrick, A
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [22] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
    Cheng, Yu
    Teng, Zan
    Zhang, Yanqiao
    Jin, Bo
    Zheng, Zhendong
    Man, Li
    Wang, Zhenghua
    Teng, Yuee
    Yu, Ping
    Shi, Jing
    Luo, Ying
    Wang, Ying
    Zhang, Jingdong
    Zhang, Huijuan
    Liu, Jiwei
    Chen, Hao
    Xiao, Jiawen
    Zhao, Lei
    Zhang, Lingyun
    Jiang, Yu
    Chen, Ying
    Zhang, Jian
    Wang, Chang
    Liu, Sa
    Qu, Jinglei
    Qu, Xiujuan
    Liu, Yunpeng
    BMC CANCER, 2024, 24 (01)
  • [23] Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study
    Morelli, M. F.
    Santomaggio, A.
    Ricevuto, E.
    Cannita, K.
    De Galitiis, F.
    Tudini, M.
    Bruera, G.
    Mancini, M.
    Pelliccione, M.
    Calista, F.
    Guglielmi, F.
    Martella, F.
    Baldi, P. Lanfiuti
    Porzio, G.
    Russo, A.
    Gebbia, N.
    Iacobelli, S.
    Marchetti, P.
    Ficorella, C.
    ONCOLOGY REPORTS, 2010, 23 (06) : 1635 - 1640
  • [24] Phase I/II study of oral uracil/tegafur (UFT®), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Hill, M
    Mackay, H
    Cunningham, D
    Glasspool, R
    Price, T
    Campbell, S
    Massey, A
    Bailey, S
    Martin, C
    Twelves, C
    ANNALS OF ONCOLOGY, 2000, 11 : 45 - 45
  • [25] Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer
    El-Rayes B
    Shields, A.
    Zalupski, M.
    Bekaii-Saab, T.
    Heilbrun, L.
    Vaishampayan, U.
    Manza, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [26] Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    El-Rayes, Bassel F.
    Zalupski, Mark M.
    Manza, Stephanie G.
    Rusin, Barbara
    Ferris, Ann Marie
    Vaishampayan, Ulka
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Shields, Anthony F.
    Philip, Philip A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (02) : 283 - 289
  • [27] Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    Bassel F. El-Rayes
    Mark M. Zalupski
    Stephanie G. Manza
    Barbara Rusin
    Ann Marie Ferris
    Ulka Vaishampayan
    Lance K. Heilbrun
    Raghu Venkatramanamoorthy
    Anthony F. Shields
    Philip A. Philip
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 283 - 289
  • [28] A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.
    Bajor, David Lawrence
    Mohamed, A. M. R.
    Selfridge, J. Eva
    Anderson, Erin E.
    Hardacre, Jeffrey
    Ammori, John Brian
    Lee, Richard T.
    Saltzman, Joel N.
    Winter, Jordan Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Correlation of circulating tumor DNA and recurrence in patients with metastatic colorectal cancer with no evidence of disease: An open-label, prospective, phase II study
    Li, Yaqi
    Hu, Xiang
    Sun, Xiaoran
    Wang, Guoqiang
    Liu, Fangqi
    Zhao, Kunli
    Li, Chengcheng
    Li, Wenhua
    Pan, Qi
    Wang, Jing
    Li, Bing
    Cai, Shangli
    Peng, Junjie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study
    Shichao Li
    Dongxiao Shen
    Qingsong Zuo
    Shengzi Wang
    Lingjia Meng
    Jiaojiao Yu
    Yang Liu
    Wusheng Li
    Chao Chen
    Peihao Yin
    Teng Chen
    Jie Wang
    Medical Oncology, 40
12345